Risk of Bleeding in Patients Undergoing Coronary Interventions on Dual and Triple Therapies: A Retrospective Study

By Staff Writer

July 20, 2023

Dual antiplatelet therapy, a combination of aspirin and clopidogrel, prasugrel or ticagrelor, is recommended for up to 12 months for secondary prevention of ischemic events among people undergoing coronary interventions. However, real-world bleeding among populations exposed to different dual antiplatelet therapy (DAPT) and triple therapy (TT) regimens has not been previously quantified. The economic impact of bleeding events is poorly characterised, particularly for minor bleeding, as is their impact on health-related quality of life.

A retrospective population-based cohort study sheds light on the bleeding risks associated with dual antiplatelet therapy and triple therapy (including an anticoagulant) in patients following coronary interventions.

Findings indicate that the incidence of bleeding was 5% in coronary artery bypass graft patients, 10% in conservatively managed acute coronary syndrome patients, and 9% in emergency percutaneous coronary intervention patients, compared to a significantly higher 18% in those on triple therapy.

Interestingly, dual antiplatelet therapy, compared to aspirin alone, increased the hazards of bleeding and major adverse cardiovascular events in coronary artery bypass grafting and conservatively managed acute coronary syndrome patients.

Moreover, among emergency percutaneous coronary intervention patients, dual antiplatelet therapy with ticagrelor (as opposed to clopidogrel) increased bleeding risks, but did not reduce major adverse cardiovascular events.

The study suggests that more potent dual antiplatelet therapy may increase bleeding risk without reducing major adverse cardiovascular events. These findings should be carefully considered by clinicians and decision-makers when recommending dual antiplatelet therapy.

There is still a need for prospective observational studies that provide high-quality data on outcomes and healthcare costs. A formal cost-effectiveness analysis could not be conducted due to the uncertainty surrounding the estimates for bleeding.

 

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.